Market openNon-fractional

Nuvation Bio/NUVB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Nuvation Bio

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Ticker

NUVB

Sector

Healthcare

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

New York, United States

Employees

159

Nuvation Bio Metrics

BasicAdvanced
$724M
Market cap
-
P/E ratio
-$0.31
EPS
1.42
Beta
-
Dividend rate
$724M
1.42
38.577
38.146
0.254
0.595
-9.20%
-11.15%
1.08
1.08
-9.953
-34.45%
-11.34%

What the Analysts think about Nuvation Bio

Analyst Ratings

Majority rating from 6 analysts.
Buy

Nuvation Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
7.30%
Profit margin
0.00%
NaN%

Nuvation Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 26.93%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.09
-$0.06
-$0.07
-
Expected
-$0.11
-$0.11
-$0.10
-$0.10
-$0.06
Surprise
-19.52%
-17.93%
-42.77%
-26.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nuvation Bio stock?

Nuvation Bio (NUVB) has a market cap of $724M as of July 05, 2024.

What is the P/E ratio for Nuvation Bio stock?

The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of July 05, 2024.

Does Nuvation Bio stock pay dividends?

No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Nuvation Bio dividend payment date?

Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.

What is the beta indicator for Nuvation Bio?

Nuvation Bio (NUVB) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Nuvation Bio stock

Buy or sell Nuvation Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing